Structure, Function, and Resistance in Chronic Myeloid Leukemia
Author:
- 1 September 2014
- journal article
- editorial
- Published by Elsevier in Cancer Cell
- Vol. 26 (3) , 305-306
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domainBlood, 2013
- Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITDBlood, 2013
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor–resistant CML: frequency and clonal relationshipsBlood, 2013
- Ponatinib in Refractory Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2012
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemiaThe Lancet Oncology, 2007
- Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid LeukemiaNew England Journal of Medicine, 2006